Quarterly report [Sections 13 or 15(d)]

Segment Information (Details)

v3.25.2
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Aug. 31, 2025
Aug. 31, 2024
Operating expenses:    
Total operating expenses $ 4,945 $ (22,437)
Operating (loss) gain (4,945) 22,437
Interest income 94 126
Interest on convertible notes $ (676) (1,165)
Amortization of discount on convertible notes   (125)
Number of reportable segments not disclosed true  
Loss on induced conversion   (1,180)
Finance charges $ (13) (14)
Loss on derivatives   (852)
Provision (benefit) for income taxes 0 0
Net (loss) income (5,540) 19,227
Share based compensation recognized in general and administrative expense 100 100
Share based compensation recognized in research and development expense 100 0
Single reporting segment | Operating segment    
Operating expenses:    
General and administrative expense 1,622 1,473
Research and development 3,144 939
Return of clinical expenses   (24,985)
Stock-based compensation expense 179 136
Total operating expenses 4,945 (22,437)
Operating (loss) gain (4,945) 22,437
Interest income 94 126
Interest on convertible notes (676) (1,165)
Amortization of discount on convertible notes   (125)
Loss on induced conversion   (1,180)
Finance charges (13) (14)
Loss on derivatives   (852)
Net (loss) income $ (5,540) $ 19,227